TY - JOUR
T1 - Terugtrekking van rofecoxib
T2 - Een signaal om voorzichtig te zijn met coxibs bij patiënten met verhoogd cardiovasculair risico
AU - Bijlsma, J. W. J.
PY - 2004/10/30
Y1 - 2004/10/30
N2 - Recently, the pharmaceutical company that manufactures rofecoxib (Vioxx) withdrew the drug on the basis of information indicating that it increases the number of acute myocardial infarctions and sudden cardiac deaths. Up until then, the advantages of selective cyclooxygenase-2 inhibitors (coxibs): notably fewer gastrointestinal complications than with the non-selective non-steroidal anti-inflammatory drugs (NSAIDs) were considered to outweigh the adverse effects. Since the other coxibs share properties with rofecoxib, such as the potential for a higher thrombotic response in treated patients, it now seems wise to refrain from prescribing coxibs in patients with an increased cardiovascular risk profile until further data are available.
AB - Recently, the pharmaceutical company that manufactures rofecoxib (Vioxx) withdrew the drug on the basis of information indicating that it increases the number of acute myocardial infarctions and sudden cardiac deaths. Up until then, the advantages of selective cyclooxygenase-2 inhibitors (coxibs): notably fewer gastrointestinal complications than with the non-selective non-steroidal anti-inflammatory drugs (NSAIDs) were considered to outweigh the adverse effects. Since the other coxibs share properties with rofecoxib, such as the potential for a higher thrombotic response in treated patients, it now seems wise to refrain from prescribing coxibs in patients with an increased cardiovascular risk profile until further data are available.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=7544237945&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/15559407
M3 - Review article
C2 - 15559407
SN - 0028-2162
VL - 148
SP - 2162
EP - 2164
JO - Nederlands tijdschrift voor geneeskunde
JF - Nederlands tijdschrift voor geneeskunde
IS - 44
ER -